← All trials
NCT04135313
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2019
- Primary completion
- Oct 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Blokhin's Russian Cancer Research CenterLead sponsor
- Blokhin's Russian Cancer Research CenterOverall official - principal investigator
- Blokhin's Russian Cancer Research CenterReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.